Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2027 (irsenontrine) in Dementia with Lewy Bodies
jRCT2080223875Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in dementia with Lewy bodies (DLB) comparing E2027 50 mg once daily with Placebo once daily (2 arms). Primary endpoint: Co-primary efficacy endpoints. Started Apr 2018; status: completed.
02
Drugs
Irsenontrine
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on jRCT2080223875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223875.